Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

"Dr. Douxfils: The main concern is probably not with ponatinib, which is reserved to patients with serious condition carrying the T315I mutation, but with drugs proposed as first-line treatment such as dasatinib or nilotinib. Therefore, we suggest that regulatory agencies trigger a complete assessment of the risk of vascular occlusive events with these drugs. There is also a need to harmonize the reporting of cardiovascular events in cancer trials and to implement specific registries to prospectively collect these data in a real-life setting. "

This is correct as Ponatinib is a third or fourth line treatment. They won't be on it long, unfortunately..... Remember, in the PACE trial, 25% of all patients has vascular events..